YOUR PARTNER
for a full Regulatory Affairs Service

Clinical Phase

When entering this most costly and exciting phase, make sure that you are working with real experts. We will champion your product and remain dedicated to the project until your medicine has reached the market and is benefiting patients.

There are some critical issues to consider in the clinical phase which if ignored will be costly in terms of time.

Can you provide evidence that your product is cost-effective, knowing that post approval you will face the 4th hurdle?

What impact will the NEW Paediatric Regulation have on your clinical programme? This needs to be considered as early as Phase 1.

New regulations demand that all Patient Information Leaflets (PIL) for new medicines need to be user tested.